Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis

Απλή σελίδα τεκμηρίου
dc.contributor.authorKatsanos, K. H.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorTsekeris, P.en
dc.contributor.authorBatistatou, A.en
dc.contributor.authorBai, M.en
dc.contributor.authorTolis, C.en
dc.contributor.authorCapizzello, A.en
dc.contributor.authorPanelos, I.en
dc.contributor.authorKaravasilis, V.en
dc.contributor.authorChristodoulou, D.en
dc.contributor.authorTsianos, E. V.en
dc.date.accessioned2015-11-24T18:38:04Z
dc.date.available2015-11-24T18:38:04Z
dc.identifier.issn1756-9966-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/17273
dc.rightsDefault Licence-
dc.subjectradioprotective agenten
dc.subjectradiation proctitisen
dc.subjecttopical applicationen
dc.subjectsmall-intestineen
dc.subjectrectal-canceren
dc.subjectrat colonen
dc.subjectwr-2721en
dc.subjecttoxicityen
dc.subjectinjuryen
dc.subjectprotectionen
dc.titleRandomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvisen
heal.abstractBackground: This study aimed to investigate the efficacy of prophylactic amifostine in reducing the risk of severe radiation colitis in cancer patients receiving radical radiotherapy to the pelvis. Methods: Patients with pelvic tumours referred for radical radiotherapy who consented participation in this trial, were randomly assigned to receive daily amifostine (A) (subcutaneously, 500 mg flat dose) before radiotherapy or radiotherapy alone (R). Sigmoidoscopy and blinded biopsies were scheduled to conduct prior to initiation and following completion of radiotherapy and again 6 to 9 months later. Radiation colitis was assessed by clinical, endoscopic and histolopathological criteria. Results: A total 44 patients were enrolled in this trial, the majority with rectal (20 patients) and cervical cancer (12 patients) and were assigned 23 in R arm and 21 in the A arm. In total 119 sigmoidoscopies were performed and 18 patients (18/44, 40.9%) were diagnosed with radiation colitis (15 grade 1 and 2, and 3 grade 3 and 4). Of them, 6 patients belonged to the A group (6/21, 28.6%) and 12 to the R group (12/23, 52.2%). Acute and grade IV radiation colitis was only developed in four patients (17.4%) in the R group. Amifostine side effects were mild. Amifostine treated patients were less likely to develop histologically detectable mucosal lesions, which indicate protection from acute mucosal injury. Conclusions: Amifostine given subcutaneously can lower the risk of acute severe radiation colitis in patients who receive radical radiotherapy to pelvic tumors.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primaryDoi 10.1186/1756-9966-29-68-
heal.identifier.secondary<Go to ISI>://000280093900001-
heal.identifier.secondaryhttp://www.jeccr.com/content/pdf/1756-9966-29-68.pdf-
heal.journalNameJournal of Experimental & Clinical Cancer Researchen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2010-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιώνel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΦΥΣ